Shattuck Labs, Inc. cotiza a 5.49 USD y tiene una capitalización bursátil de $551M. En los últimos 12 meses ha facturado $1M con un margen de flujo de caja libre del -3995.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | — | $-0.12 | $-0.13 |
| Estimado | $-0.11 | $-0.12 | $-0.12 | $-0.13 |
| Sorpresa | — | — | +0.0% | +0.0% |
| Métrica | STTK | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -5150.8% | -38.6% | -5112.2% |
| Net Margin | -4880.9% | -33.6% | -4847.3% |
| FCF Margin | -3995.3% | -13.9% | -3981.4% |
| ROE | -59.2% | -40.4% | -18.8% |
| ROA | -53.6% | -32.0% | -21.6% |
| Current Ratio | 11.70 | 2.84 | +8.86 |
| Debt / Equity | — | 0.28 | — |